The STAR study: A real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis

Clinical Therapeutics

Volumn 36, Issue 12, 2014, Pages 1946-1957

  Hupperts, Raymond ^a   Ghazi Visser, Lizette ^b   Martins Silva, Ana ^c   Arvanitis, Michalis ^d   Kuusisto, Hanna ^e   Marhardt, Kurt ^f   Vlaikidis, Nikolaos ^g  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Merck BV Schiphol Rijk   (Netherlands)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^d Merck AE Hellas ^*  (Greece)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f Merck Gesellschaft mbH   (Austria)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

adherence; injection site reactions; injection subcutaneous; interferon 1a

Indexed keywords

AMINOTRANSFERASE; BETA1A INTERFERON; IBUPROFEN; METHYLPREDNISOLONE; PARACETAMOL;

ADULT; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ASSESSMENT; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEMATOMA; HUMAN; HYPERHIDROSIS; INCIDENCE; INJECTION SITE ABSCESS; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; LIMB PAIN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PSYCHOSIS; RECURRENCE RISK; RECURRENT DISEASE; SELF INJECTION; SKIN MANIFESTATION; SLEEP DISORDER; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON BETA-1A; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84918533784     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.04.002     Document Type: Article

References (33)

1. K. Costello, P. Kennedy, and J. Scanzillo Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term Medscape J Med 10 2008 225
2. M.W. Reynolds, R. Stephen, and C. Seaman Persistence and adherence to disease modifying drugs among patients with multiple sclerosis Curr Med Res Opin 26 2010 663 674
3. K. Treadaway, G. Cutter, and A. Salter Factors that influence adherence with disease-modifying therapy in MS J Neurol 256 2009 568 576
4. H.L. Tremlett, and J. Oger Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS Neurology 61 2003 551 554
5. D.W. Brandes, T. Callender, and E. Lathi A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events Curr Med Res Opin 25 2009 77 92
6. B. Uitdehaag, C. Constantinescu, and P. Cornelisse Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study Ther Adv Neurol Disord 4 2011 3 14
7. A. Al-Sabbagh, R. Bennet, and C. Kozma Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database J Neurol. 255 2008 S79
8. S.C. Steinberg, R.J. Faris, and C.F. Chang Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study Clin Drug Investig 30 2010 89 100
9. J.I. Ivanova, R.E. Bergman, and H.G. Birnbaum Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US J Med Econ 15 2012 601 609
10. L. Kappos, A. Traboulsee, and C. Constantinescu Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS Neurology 67 2006 944 953
11. K.P. Johnson, B.R. Brooks, and J.A. Cohen Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1995 1268 1276
12. K.P. Johnson, B.R. Brooks, and J.A. Cohen Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group Neurology 50 1998 701 708
13. G. Comi, V. Martinelli, and M. Rodegher Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1503 1511
14. L. Kappos, C.H. Polman, and M.S. Freedman Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 2006 1242 1249
15. L.D. Jacobs, R.W. Beck, and J.H. Simon Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group N Engl J Med 343 2000 898 904
16. R.P. Kinkel, C. Kollman, and P. O'Connor IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event Neurology 66 2006 678 684
17. D. Cox, and J. Stone Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis J Neurosci Nurs 38 2006 167 171
18. D.C. Mohr, A.C. Boudewyn, and W. Likosky Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject Ann Behav Med 23 2001 125 132
19. J. de Seze, F. Borgel, and F. Brudon Patient perceptions of multiple sclerosis and its treatment Patient Prefer Adherence 6 2012 263 273
20. V. Devonshire, Y. Lapierre, and R. Macdonell The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis Eur J Neurol 18 2011 69 77
21. G. Comi, N. De Stefano, and M.S. Freedman Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial Lancet Neurol 11 2012 33 41
22. G. Giovannoni, O. Barbarash, and F. Casset-Semanaz Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results Mult Scler 15 2009 219 228
23. C.H. Polman, S.C. Reingold, and G. Edan Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria" Ann Neurol 58 2005 840 846
24. ® European Summary of Product Characteristics, 2014.
25. E.E. Gulick, C.F. Waltz, and O.L. Stickland The self-administered ADL scale for persons with multiple sclerosis C. Waltz, O. Stickland, Measurement of Nursing Outcomes. Vol I: Measuring Client Outcomes 1988 Springer New York, NY 128 159
26. G. Giovannoni, O. Barbarash, and F. Casset-Semanaz Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, Phase IIIb study in adults with multiple sclerosis Clin Ther 29 2007 1128 1145
27. N. De Stefano, M.P. Sormani, and B. Stubinski Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study J Neurol Sci 312 2012 97 101
28. E. Portaccio, and M.P. Amato Improving compliance with interferon-beta therapy in patients with multiple sclerosis CNS Drugs 23 2009 453 462
29. K.E. O'Rourke, and M. Hutchinson Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns Mult Scler 11 2005 46 50
30. R. Gold, P. Rieckmann, and P. Chang The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study Eur J Neurol 12 2005 649 656
31. R.M. Ruggieri, N. Settipani, and L. Viviano Long-term interferon-beta treatment for multiple sclerosis Neurol Sci 24 2003 361 364
32. G. Giovannoni, E. Southam, and E. Waubant Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence Mult Scler 18 2012 932 946
33. A. Lugaresi, C. Florio, and V. Brescia-Morra Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study BMC Neurol 12 2012 7